Canopy Growth stock tumbles after announcing $200 million share sale plan
ATLANTA - Artivion, Inc. (NYSE:AORT) saw its shares plunge 10% after-hours Monday after the cardiac and vascular surgery company reported fourth quarter revenue that fell short of analyst expectations and provided disappointing guidance for 2025.
The company posted Q4 revenue of $97.3 million, up 4% year-over-year but below the consensus estimate of $100.82 million. Adjusted earnings per share came in at breakeven, beating expectations for a loss of $0.06 per share.
For the full year 2025, Artivion forecasts revenue between $420 million and $435 million, with the midpoint of $427.5 million falling below Wall Street’s projection of $430.2 million.
The revenue miss and weak outlook overshadowed Artivion’s improved profitability, as adjusted EBITDA rose 15% YoY to $17.6 million in Q4.
"2024 was an excellent year for Artivion, marked by robust revenue and adjusted EBITDA growth," said Pat Mackin, Chairman, President, and CEO. However, he noted that Q4 revenues were "negatively impacted" by a late November cybersecurity incident.
On a positive note, the company highlighted regulatory progress for its AMDS Hybrid Prosthesis, receiving a Humanitarian Device Exemption from the FDA and submitting the second module of its pre-market approval application.
Despite the setback, management remains confident in achieving double-digit revenue growth and accelerated adjusted EBITDA expansion in 2025. The company expects currency headwinds to reduce reported revenue growth by approximately 2% for the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.